Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
An Assessment of Milk Thistle Pharmacokinetics and Drug Interactions
This study is currently recruiting participants.
Verified by National Center for Complementary and Alternative Medicine (NCCAM), August 2008
Sponsors and Collaborators: National Center for Complementary and Alternative Medicine (NCCAM)
Office of Dietary Supplements (ODS)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier: NCT00200798
  Purpose

There is accumulating evidence from various sources that extracts from the milk thistle plant can be useful in the treatment of a variety of liver ailments as well as other disorders. This investigation will essentially be composed of two individual normal volunteer studies of milk thistle. The first study will assess the rate and extent of absorption of components of a standardized botanical extract obtained from the milk thistle plant. This first study is termed a bioavailability study. This investigation will take approximately 8 weeks and involve 10 clinic visits. Secondly, a drug interaction study will be performed. This is an assessment study of the potential for this botanical extract to interact with other prescription or over-the-counter medications. This study is also expected to take approximately 8 weeks but will involve 18 clinic visits. In both studies all subjects will receive the same milk thistle supplement and no placebo will be administered.


Condition Phase
Healthy
Phase II

Drug Information available for: Silymarin
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: Pharmacokinetics and Drug Interactions With Milk Thistle

Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

plasma & urine


Estimated Enrollment: 32
Study Start Date: May 2006
Estimated Study Completion Date: August 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Normal healthy volunteers

Criteria

Inclusion Criteria:

  • Age range: 18-45 years old
  • Race or ethnicity: no restrictions
  • Health status: subjects must have no clinically significant diseases or clinically significant abnormal laboratory values as assessed during the screening medical history, physical exam, and laboratory evaluations.
  • Must have no history of significant psychiatric illness or substance use.
  • Written Informed Consent as well as Health Insurance Portability and Accountability Act (HIPAA) authorization forms must be signed by the eligible subject prior to the initiation of any study procedures.

Exclusion Criteria:

Any of the following conditions are cause for exclusion and/or discontinuation from the study:

  • The presence of any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion.
  • A positive urine pregnancy test
  • The use of oral contraceptives
  • The lack of use of acceptable barrier methods of birth control unless abstinent
  • The use of any concomitant medication including herbal medications, over-the-counter (OTC) supplements, or a history of hypersensitivity to DM, ALPZ, TOL, or caffeine (CAF) and any history of sensitivity to milk thistle or any of its components.
  • Subjects genotyped as poor metabolizers of CYP2D6 at screening
  • Active smoking or use of CAF containing beverage (coffee, certain colas) for one week prior and during the study period due to known effects on CYP1A2 activity.
  • Subjects expressing inability to conform to dietary restrictions required for the study
  • The use of any illicit drugs or habitual consumption of large quantities of ethanol (> 3 drinks/day)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00200798

Contacts
Contact: John S. Markowitz, Pharm.D. 843-792-0172 markowij@musc.edu
Contact: Jennifer L. Donovan, Ph.D. 843-792-5589 donovanj@musc.edu

Locations
United States, South Carolina
Medical University of South Carolina, GCRC Recruiting
Charleston, South Carolina, United States, 29425
Sub-Investigator: Jennifer L. Donovan, Ph.D.            
Sponsors and Collaborators
Investigators
Principal Investigator: John S. Markowitz, Pharm.D. Medical University of South Carolina
  More Information

Responsible Party: MUSC ( John S. Markowitz, Pharm.D. )
Study ID Numbers: R21 AT002817-01
Study First Received: September 13, 2005
Last Updated: August 14, 2008
ClinicalTrials.gov Identifier: NCT00200798  
Health Authority: United States: Federal Government

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
Milk Thistle
Silymarin
pharmacokinetics
drug interactions
Normal volunteers

Study placed in the following topic categories:
Silymarin
Healthy

ClinicalTrials.gov processed this record on January 16, 2009